Background Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the
European Medicines Agency and the US Food and Drug Administration for the treatment of …

Aims Patients diagnosed with idiopathic pulmonary fibrosis (IPF) have a high symptom
burden and numerous needs that remain largely unaddressed despite advances in …

Background The processes that result in progression of idiopathic pulmonary fibrosis (IPF)
remain enigmatic. Moreover, the course of this disease can be highly variable and difficult to …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive parenchymal lung disease
characterized by a median survival of 3–5 years following diagnosis. The diagnosis is based …

Background Idiopathic pulmonary fibrosis (IPF) is characterised by worsening dyspnoea and
exercise intolerance. Research question Does a long-term pulmonary rehabilitation improve …

Introduction PROOF (a Prospective Observational Registry to Describe the Disease Course
and Outcomes of Idiopathic Pulmonary Fibrosis) is an ongoing, observational registry …

Idiopathic pulmonary fibrosis (IPF), the most common form of fibrosing idiopathic interstitial
pneumonia, is an inexorably progressive disease with a 5-year survival of~ 20%. In the last …

Idiopathic pulmonary fibrosis (IPF) is a rare pulmonary disease with a poor prognosis and
severe impact on quality of life. Early diagnosis is still challenging and important delays are …

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive parenchymal scarring,
leading to dyspnoea, respiratory failure and premature death. Although IPF is confined to the …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive diffuse parenchymal lung
disease of unknown origin, with a mortality rate exceeding that of many cancers. The …